Anthropic's $30B funding round at a $380B valuation represents concentration of late-stage venture capital in US AI infrastructure, while global healthcare investors deploy across earlier-stage opportunities spanning FDA, EMA, and Asia-Pacific regulatory pathways.1
Australian firm Brandon Capital, US-based Roseland Advisors, and European-focused ADAR1 Capital Management are leading investments in clinical-stage therapeutics. R1 Therapeutics, Equillium, and Germany's Biofrontera have secured institutional backing as investors target companies with multi-jurisdictional regulatory strategies.23
March 2026 deal flow shows Series A through C concentration across North America, Europe, and Asia. US firms Union Square Ventures and Blockchain Capital are deploying beyond traditional sectors into medical robotics, AI applications, and quantum computing. Netherlands-based Vitestro raised funding for blood-drawing robotics, while Singapore's Atomionics and UK's Isembard closed quantum computing rounds.1
Equillium's Q3 2025 results showed pipeline progress relevant to FDA and international regulators. Biofrontera's Q4 2025 earnings demonstrated revenue generation across European and US dermatology markets, attracting growth-stage capital from multiple geographies.23
The bifurcation creates distinct geographic and risk profiles. AI infrastructure rounds concentrate in Silicon Valley with compressed timeframes and massive check sizes limiting participation to US mega-funds. Healthcare deals span global jurisdictions with longer cycles but multiple inflection points through clinical readouts and regulatory approvals across FDA, EMA, and PMDA pathways.
International healthcare funds benefit from lower entry valuations versus US AI infrastructure while maintaining technology exposure through medical devices and AI-enabled diagnostics developed for global markets. This positioning allows participation in healthcare's technology transformation without competing for oversubscribed late-stage AI deals concentrated in California.
Deal volume in therapeutics across North America, Europe, and Australia suggests VCs view healthcare as offering sustainable returns despite longer hold periods. Clinical-stage companies with multi-market regulatory strategies provide milestone-driven risk reduction contrasting with AI infrastructure's binary deployment risk at elevated valuations.
